

L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:182670 CAPLUS Full-text
 DN 142:280235
 TI Process for preparation of 2-(4-acetylpiperazin-1-yl)-6-[3,5-bis(trifluoromethyl)phenylmethyl]-4-(2-methylphenyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one
 IN Araya, Ichiro; Kanazawa, Shintaro
 PA Kyorin Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2

DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005019225	A1	20050303	WO 2004-JP11965	20040820
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2003-297870 A 20030821

AB This invention pertains to a method for producing the title compound having excellent antagonistic activity against tachykinin receptor, especially NK1 receptor. For example, the title compound was prepared starting from 3,5-bis(trifluoromethyl)benzaldehyde and 2-methylbenzaldehyde in a multi-step synthesis including a cyclization key step in good yield. This invention provides a convenient method to prepare the title compound in high yield and high purity with industrial advantages.


IT 569683-18-7P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of 2-(4-acetylpiperazin-1-yl)-6-[3,5-bis(trifluoromethyl)phenylmethyl]-4-(2-methylphenyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one)


RN 569683-18-7 CAPLUS

CN Piperazine, 1-acetyl-4-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]-(9CI) (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:130315 CAPLUS Full-text
 DN 142:373813
 TI 2-Substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one as a structurally new NK1 antagonist
 AU Seto, Shigeki; Tanioka, Asao; Ikeda, Makoto; Izawa, Shigeru
 CS Discovery Research Laboratories, Ltd, Kyorin Pharmaceutical Co., Tochigi, 329-0114, Japan
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(5), 1485-1488
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 GI



AB The structurally novel pyrimido[4,5-b][1,5]oxazocine derivative I, a hybrid compound of pyrido[4,3-b]- and [2,3-b]-1,5-oxazocine, was designed and synthesized. The authors examined the atropisomeric property and the NK1 antagonist activity of I. Compound I was found to possess features of both pyrido[4,3-b]- and [2,3-b]-1,5-oxazocines, free rotation about the biaryl bond as in the former, and potent in vivo activity as in the latter.


IT **569683-10-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one as a structurally new NK1 antagonist)

RN 569683-10-9 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-2-[4-(1-pyrrolidinyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

App's

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:591188 CAPLUS Full-text
 DN 139:149648
 TI Preparation of fused bicyclic pyrimidine derivatives as tachykinin antagonists
 IN Seto, Shigeki; Tanioka, Asao; Ikeda, Makoto; Izawa, Shigeru
 PA Kyorin Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003062245	A1	20030731	WO 2003-JP263	20030115
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2472835	AA	20030731	CA 2003-2472835	20030115
	EP 1473295	A1	20041103	EP 2003-700567	20030115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007156	A	20041207	BR 2003-7156	20030115
	US 2005085469	A1	20050421	US 2003-501551	20030115
PRAI	JP 2002-9373	A	20020118		
	WO 2003-JP263	W	20030115		
OS	MARPAT 139:149648				
GI					



AB The title compds. I [the rings A and B represent each a benzene ring optionally having 1 to 3 substituents (wherein 2 adjacent substituents may be bonded to each other to form a ring); the ring C represents a nitrogen-containing ring; m is 1 or 2; A1 = (CH2)n; and n is 2 or 3] are prepared. Compds. of this invention in vitro showed Kb values of 0.00631 nmol/L to 0.798 nmol/L in a test for NK1 receptor antagonism.


IT 569682-88-8P 569682-90-2P 569682-92-4P
 569682-94-6P 569682-96-8P 569682-98-0P
 569683-00-7P 569683-02-9P 569683-04-1P
 569683-06-3P 569683-08-5P 569683-10-9P
 569683-12-1P 569683-14-3P 569683-16-5P
 569683-18-7P 569683-20-1P 569683-22-3P
 569683-24-5P 569683-26-7P 569683-29-0P
 569683-31-4P 569683-33-6P 569683-35-8P
 569683-37-0P 569683-38-1P 569683-40-5P
 569683-42-7P 569683-44-9P 569683-46-1P

569683-48-3P 569683-50-7P 569683-52-9P
 569683-54-1P 569683-56-3P 569683-58-5P
 569683-60-9P 569683-62-1P 569683-64-3P
 569683-66-5P 569683-69-8P 569683-71-2P
 569683-73-4P 569683-75-6P 569683-77-8P
 569683-79-0P 569683-80-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of fused bicyclic pyrimidine derivs. as tachykinin antagonists)


RN 569682-88-8 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-2-(4-morpholinyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 569682-90-2 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-fluorophenyl)-6,7,8,9-tetrahydro-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 569682-92-4 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 569682-94-6 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-6,7,8,9-tetrahydro-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 569682-96-8 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-6,7,8,9-tetrahydro-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 569682-98-0 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2,4-difluorophenyl)-6,7,8,9-tetrahydro-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 569683-00-7 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(4-methoxyphenyl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 569683-02-9 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2,4-dimethoxyphenyl)-6,7,8,9-tetrahydro-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 569683-04-1 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-[4-(dimethylamino)phenyl]-6,7,8,9-tetrahydro-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 569683-06-3 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methoxyphenyl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 569683-08-5 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-phenyl-2-[4-(1-pyrrolidinyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 569683-10-9 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-2-[4-(1-pyrrolidinyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 569683-12-1 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-6,7,8,9-tetrahydro-2-[4-(1-pyrrolidinyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 569683-14-3 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 569683-16-5 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-2-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 569683-18-7 CAPLUS

CN Piperazine, 1-acetyl-4-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]- (9CI) (CA INDEX NAME)




RN 569683-20-1 CAPLUS

CN 1-Piperazinecarboxaldehyde, 4-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]- (9CI) (CA INDEX NAME)




RN 569683-22-3 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-2-(1H-imidazol-1-yl)-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 569683-24-5 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-2-(1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)




RN 569683-26-7 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(1,1-dioxido-4-thiomorpholinyl)-6,7,8,9-tetrahydro-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 569683-29-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 569683-31-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 569683-33-6 CAPLUS


CN 3-Piperidinecarboxamide, 1-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]- (9CI) (CA INDEX NAME)



RN 569683-35-8 CAPLUS


CN 4-Piperidinecarboxamide, 1-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-

6,7,8,9-tetrahydro-4-(2-methylphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]- (9CI) (CA INDEX NAME)




RN 569683-37-0 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[3-(dimethylamino)-1-pyrrolidinyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 569683-38-1 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-6,7,8,9-tetrahydro-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 569683-40-5 CAPLUS

CN Acetamide, N-[1-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RN 569683-42-7 CAPLUS

CN Piperazine, 1-acetyl-4-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-6,7,8,9-tetrahydro-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]- (9CI) (CA INDEX NAME)




RN 569683-44-9 CAPLUS

CN Piperazine, 1-acetyl-4-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methoxyphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]- (9CI) (CA INDEX NAME)




RN 569683-46-1 CAPLUS

CN Piperazine, 1-acetyl-4-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-5-oxo-4-phenyl-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]- (9CI) (CA INDEX NAME)




RN 569683-48-3 CAPLUS

CN Piperazine, 1-acetyl-4-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluoro-2-methylphenyl)-6,7,8,9-tetrahydro-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]- (9CI) (CA INDEX NAME)




RN 569683-50-7 CAPLUS

CN Piperazine, 1-acetyl-4-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5,6,7,8-tetrahydro-4-(2-methylphenyl)-5-oxopyrimido[5,4-f][1,4]oxazepin-2-yl]- (9CI) (CA INDEX NAME)




RN 569683-52-9 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-2-[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 569683-54-1 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-2-[4-(4-morpholinyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 569683-56-3 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[4-(dimethylamino)-1-piperidinyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 569683-58-5 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 2-[1,4'-bipiperidin]-1'-yl-6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 569683-60-9 CAPLUS

CN Acetamide, N-[1-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 569683-62-1 CAPLUS

CN Methanesulfonamide, N-[1-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 569683-64-3 CAPLUS

CN Piperazine, 1-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 569683-66-5 CAPLUS

CN 1H-1,4-Diazepine, 1-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]hexahydro-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 569683-69-8 CAPLUS

CN 1H-1,4-Diazepine, 1-acetyl-4-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]hexahydro- (9CI) (CA INDEX NAME)




RN 569683-71-2 CAPLUS

CN Acetamide, N-[1-[6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methylphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 569683-73-4 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(1,1-dioxido-4-thiomorpholinyl)-6,7,8,9-tetrahydro-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 569683-75-6 CAPLUS

CN 5H-Pyrimido[4,5-b][1,5]oxazocin-5-one, 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-4-(2-methoxyphenyl)-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 569683-77-8 CAPLUS

CN Piperazine, 1-acetyl-4-[6,7,8,9-tetrahydro-4-(2-methoxyphenyl)-5-oxo-6-(phenylmethyl)-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]- (9CI) (CA INDEX NAME)




RN 569683-79-0 CAPLUS

CN Piperazine, 1-acetyl-4-[6,7,8,9-tetrahydro-4-(2-methoxyphenyl)-6-[(2-methoxyphenyl)methyl]-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]- (9CI) (CA INDEX NAME)



RN 569683-80-3 CAPLUS


CN Piperazine, 1-acetyl-4-[6-[(4-fluorophenyl)methyl]-6,7,8,9-tetrahydro-4-(2-methoxyphenyl)-5-oxo-5H-pyrimido[4,5-b][1,5]oxazocin-2-yl]- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 1 OF 1 MARPAT COPYRIGHT 2005 ACS on STN
 AN 139:292279 MARPAT Full-text
 TI Preparation of 2,3,4,5-tetrahydro-6H-pyrido[4,3-b][1,5]oxazocine derivatives as tachykinin receptor antagonists
 IN Seto, Shigeki; Tanioka, Aso; Ikeda, Makoto; Izawa, Shigeru
 PA Kyorin Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 23 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003277384	A2	20031002	JP 2002-84760	20020326
PRAI	JP 2002-84760		20020326		
GI					




AB The title compds. I [wherein rings A and B = independently (un)substituted Ph; ring C = (un)substituted heterocycle; m = 1 or 2; n = 2 or 3] and salts thereof are prepared as tachykinin receptor, especially NK1 receptor, antagonists. Thus, the compound II was prepared in a multi-step synthesis. I showed inhibitory activity against NK1 receptor with Kb of 0.151 to 0.440 nM in guinea pig. I are useful as drugs for the treatment of urination disorder (no data).

MSTR 1



G1 = Ph (SO (1-3) G2)
 G4 = 28




G8 = (1-2) CH2
 G9 = (2-3) CH2
 G14 = Ph (SO (1-3) G2)

MPL: claim 1

NTE: or salts

NTE: additional ring and oxo formation also claimed

=> d l2; d his; log y
 L2 HAS NO ANSWERS
 L1 STR



Structure attributes must be viewed using STN Express query preparation.
 L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 19:10:33 ON 09 JUN 2005)

FILE 'REGISTRY' ENTERED AT 19:10:41 ON 09 JUN 2005

L1 STRUCTURE UPLOADED
 L2 QUE L1
 L3 1 S L2
 L4 47 S L2 FUL

FILE 'CAPLUS' ENTERED AT 19:11:14 ON 09 JUN 2005

L5 3 S L4

FILE 'BEILSTEIN' ENTERED AT 19:11:44 ON 09 JUN 2005

L6 0 S L2
 L7 0 S L2 FUL

FILE 'MARPAT' ENTERED AT 19:12:08 ON 09 JUN 2005

L8 1 S L2
 L9 2 S L2 FUL
 L10 1 S L9 NOT L5

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	118.15	295.02
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.68	-2.87

STN INTERNATIONAL LOGOFF AT 19:12:46 ON 09 JUN 2005